Inhibikase Therapeutics (IKT) Share-based Compensation (2020 - 2026)
Inhibikase Therapeutics (IKT) posted Share-based Compensation of $5.35 million for Q2 2026, up 27.0% from $4.21 million a year earlier but down 3.8% from the prior quarter.
Powered by 
Analysis
Inhibikase Therapeutics (IKT) Share-based Compensation (2020 - 2026) Analysis & Trends
For the trailing twelve months through Jun 30, 2026, Share-based Compensation at Inhibikase Therapeutics was $19.96 million, up 39.5% year-over-year; for FY2025, it came in at $15.31 million, up 88.1% from FY2024.
- Annual Share-based Compensation shows a five-year compound annual growth rate of 92.9% (FY2020 to FY2025).
- In prior years, Inhibikase Therapeutics' Share-based Compensation was $8.14 million in FY2024, $500,148 in FY2023 (+9.2%), $458,147 in FY2022 (-70.1%) and $1.53 million in FY2021 (+167.0%).
- Quarterly Share-based Compensation has run from a low of $30,697 in Q2 2024 to a high of $7.91 million in Q4 2024 over five years.
- On a year-over-year basis, Share-based Compensation increased in three of the last four quarters, with growth averaging 42.7%.
- The strongest year-over-year quarter for Share-based Compensation in the past five years was Q1 2026, with growth of 172.2%; the weakest was Q1 2022, with a decline of 79.2%.
- According to Business Quant data, Share-based Compensation for the three prior quarters was $5.56 million (Q1 2026), $4.53 million (Q4 2025) and $4.53 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 458.00 Mn |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | 166.00 Mn |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 298.00 Mn |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | - |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 165.00 Mn |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | 231.00 Mn |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 249.00 Mn |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 170.20 Mn |
| 10 | Inhibikase Therapeutics | 357.87 Mn | -227.60 Mn | - | 5.35 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 5.35 Mn |
| Mar 31, 2026 | 5.56 Mn |
| Dec 31, 2025 | 4.53 Mn |
| Sep 30, 2025 | 4.53 Mn |
| Jun 30, 2025 | 4.21 Mn |
| Mar 31, 2025 | 2.04 Mn |
| Dec 31, 2024 | 7.91 Mn |
| Sep 30, 2024 | 148,024.00 |
| Jun 30, 2024 | 30,697.00 |
| Mar 31, 2024 | 53,434.00 |
| Dec 31, 2023 | 122,249.00 |
| Sep 30, 2023 | 129,781.00 |
| Jun 30, 2023 | 124,845.00 |
| Mar 31, 2023 | 123,273.00 |
| Dec 31, 2022 | 100,363.00 |
| Sep 30, 2022 | 101,788.00 |
| Jun 30, 2022 | 132,767.00 |
| Mar 31, 2022 | 123,229.00 |
| Dec 31, 2021 | 265,850.00 |
| Sep 30, 2021 | 352,419.00 |
API Access
Inhibikase Therapeutics Share-based Compensation API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=share-based-compensation&ticker=IKT&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "share-based-compensation", "ticker": "IKT", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=share-based-compensation&ticker=IKT&period=max&api_key=YOUR_API_KEY");
const data = await res.json();